|
|
|
| Expressions and significances of estrogen receptor, progesterone recetor,P-glycoprotein, glutathione-s-transferases-π, P-glycoprotein Ⅱin breast cancer |
| YAN Xia CAI Li TANG Hai-xu WU Ping▲ |
| Department of Pathology, Maternal and Child Health Care Center of Huai′an City in Jiangsu Province, Huai′an 223001, China |
|
|
|
|
Abstract Objective To explore the expression of estrogen receptor (ER), progesterone recetor (PR), P-glycoprotein(P-gp), glutathione-s-transferases π (GST-π) and P-glycoprotein Ⅱ (Topo Ⅱ) in breast cancer. Methods A total of 91 cases of specimens of breast cancer diagnosed by pathology after surgical excision in Huai′an Maternal and Child Health Hospital from September 2010 to January 2014 were selected. The expression of ER, PR, GST-π, P-gP, TopoⅡin 91 patients from breast cancer tissues were detected by immunohistochemistry technique. Results The expression of ER, PR, GST-π, Topo Ⅱwere significantly associated with histological grades, there existed correlation between Topo Ⅱand lympnode metastasis, P-gP expression was significantly associated with tumor size. The expression of ER was positively correlated with the expression of PR (r=0.637, P=0.000). Conclusion The detection of the expression of ER, PR, GST-π, P-gP, Topo Ⅱhave important meaning for assessing the prognosis of patients with breast cancer and chemtherapy options.
|
|
|
|
|
|
| [1] |
樊鑫鑫，吕慧芳，陈贝贝，等.乳腺癌术后辅助化疗前后HER-2 表达改变1 例[J].河南医学研究，2017，26（3）：446-447.
|
| [2] |
Lakhani SR，Ellis IO，Schnitt SJ，et al.WHO classification of tumours of the breastst[M].Lyon，France：IARC Press，2012.
|
| [3] |
王梅，顾军，沈晓莹，等.中国上海地区乳腺癌的临床病理特征分析[J].临床肿瘤学杂志，2012，17（5）：437-441.
|
| [4] |
张涛.ER、PR、Cerb-B2、P53 蛋白、LRP、GST-π、TopoⅡ在乳腺粘液癌中的表达[D].遵义：遵义医学院，2009：1-41.
|
| [6] |
杜璟，张晓丽，蒋丽娜.雌、孕激素受体和表皮生长因子受体在乳腺癌中的表达及其临床意义[J].中国老年学杂志，2014，34（19）：5405-5407.
|
| [7] |
李维权，宋茂民.HER-2、P53、Ki-67、Nm23、ER、PR 蛋白在乳腺癌中的表达及临床意义[J].标记免疫分析与临床，2011，18（1）：18-22.
|
| [8] |
李占文，杨华锋，胡云锵，等.P-gp、GST-π、Topo Ⅱ在乳腺癌中的表达及其意义[J].浙江医学，2007，29（9）：919-921.
|
| [9] |
陈萍，刘新兰，崔洁.GST-π、Topo Ⅱ、ER、PR 在乳腺癌组织中的表达及其临床意义[J].宁夏医学杂志，2008，30（1）：13-15.
|
| [5] |
Zhang Z，Wang J，Skinner KA，et al.Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression[J].Histopathology，2014，65（4）：508-516.
|
| [10] |
徐光辉，叶胜龙，郑义同，等.人乳腺癌中3 种耐药基因产物的表达及其与预后的相关性[J].复旦学报（医学版），2005，32（1）：33-35.
|
| [11] |
张成晨.叶酸靶向和药物共载的聚合物纳米胶束逆转肿瘤多药耐药性及其荧光成像研究[D].成都：电子科技大学，2017：1-71.
|
| [12] |
桂贤，刘会敏.肿瘤多药耐药发生机制的研究进展[J].上海医学，2005，28（2）：16l-164.
|
| [13] |
Pusztai L，Wagner P，Ibrallim N，et al.Phase Ⅱstudy of Tariquidar，a selective P-glycoprotein inhibitor，in patients with chemotherapy-re-sistant，advanced breast carcinoma[J].Cancer，2005，104（4）：682-691.
|
| [14] |
邓再兴，谢贝，俞文菊.乳腺癌P-gp、GST-π 及TopoⅡ的表达及意义[J].肿瘤研究与临床，2005，17（1）：13-15.
|
| [15] |
孙丽梅，王鲁建，宋敏，等.乳腺癌中耐药蛋白P-gp、GST-π、Topo-Ⅱ的表达[J].中国组织化学与细胞化学杂志，2006，15（2）：169-172.
|
|
|
|
